Recombinant CCR5 (Leronlimab Biosimilar) antibody

Catalog No. ABIN7488173

This Mammalian Cells Monoclonal antibody specifically detects CCR5 (Leronlimab Biosimilar) in ELISA. It exhibits reactivity toward Human.

Quick Overview for Recombinant CCR5 (Leronlimab Biosimilar) antibody (ABIN7488173)

Target: CCR5 (Leronlimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This CCR5 (Leronlimab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-CCR5 (Leronlimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Leronlimab Biosimilar - Anti-CCR5, CD195 mAb

Characteristics: Antibody Type: IgG4-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG4 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for CCR5 (Leronlimab Biosimilar)

Target: CCR5 (Leronlimab Biosimilar)

Target Type: Biosimilar

Background: HuPRO-140,PA-14,PRO-140
Leronlimab, a monoclonal antibody blocker of C-C chemokine receptor type 5 originally developed to treat human immunodeficiency virus infection, was administered as an open-label compassionate-use therapeutic for coronavirus disease 2019 (COVID-19).

CAS-No: 674782-26-4